Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Apr 7, 2026; 32(13): 116481
Published online Apr 7, 2026. doi: 10.3748/wjg.v32.i13.116481
Published online Apr 7, 2026. doi: 10.3748/wjg.v32.i13.116481
Letter to the Editor: AADN score predicts overall and progression-free survival in triple therapy for hepatocellular carcinoma
Cristian Lindner, Department of Radiology, Faculty of Medicine, University of Concepción, Concepción 4030000, Chile
Cristian Lindner, Department of Radiology, Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción 4030000, Chile
Author contributions: Lindner C wrote this manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Cristian Lindner, MD, Doctor, Department of Radiology, Faculty of Medicine, University of Concepción, San Martín 1436, Concepción 4030000, Chile.
Received: November 13, 2025
Revised: December 18, 2025
Accepted: January 19, 2026
Published online: April 7, 2026
Processing time: 135 Days and 4 Hours
Revised: December 18, 2025
Accepted: January 19, 2026
Published online: April 7, 2026
Processing time: 135 Days and 4 Hours
Core Tip
Core Tip: The AADN score, derived from alpha-fetoprotein, alkaline phosphatase, direct bilirubin, and neutrophil-to-lymphocyte ratio, provides a simple yet powerful tool to predict overall and progression-free survival in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization, sintilimab, and lenvatinib. By integrating markers of tumor biology, hepatic function, and systemic inflammation, this model enables individualized risk stratification and supports precision-based decision-making in triple therapy for hepatocellular carcinoma.